PL2354161T3 - Przeciwciało anty -NR10 i jego zastosowanie - Google Patents
Przeciwciało anty -NR10 i jego zastosowanieInfo
- Publication number
- PL2354161T3 PL2354161T3 PL09830463T PL09830463T PL2354161T3 PL 2354161 T3 PL2354161 T3 PL 2354161T3 PL 09830463 T PL09830463 T PL 09830463T PL 09830463 T PL09830463 T PL 09830463T PL 2354161 T3 PL2354161 T3 PL 2354161T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2008/072152 WO2009072604A1 (ja) | 2007-12-05 | 2008-12-05 | 抗nr10抗体、およびその利用 |
PCT/JP2009/054941 WO2010064456A1 (ja) | 2008-12-05 | 2009-03-13 | 抗nr10抗体、およびその利用 |
PCT/JP2009/070376 WO2010064697A1 (ja) | 2008-12-05 | 2009-12-04 | 抗nr10抗体、およびその利用 |
EP09830463.7A EP2354161B1 (en) | 2008-12-05 | 2009-12-04 | Anti-nr10 antibody, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2354161T3 true PL2354161T3 (pl) | 2016-01-29 |
Family
ID=42233344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09830463T PL2354161T3 (pl) | 2008-12-05 | 2009-12-04 | Przeciwciało anty -NR10 i jego zastosowanie |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2949672A1 (pl) |
JP (1) | JP2010210772A (pl) |
KR (1) | KR101271323B1 (pl) |
BR (1) | BRPI0906478B8 (pl) |
DK (1) | DK2354161T3 (pl) |
ES (1) | ES2552690T3 (pl) |
PL (1) | PL2354161T3 (pl) |
PT (1) | PT2354161E (pl) |
RU (1) | RU2487136C2 (pl) |
WO (1) | WO2010064697A1 (pl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
KR20150091545A (ko) | 2006-06-08 | 2015-08-11 | 추가이 세이야쿠 가부시키가이샤 | 염증성 질환의 예방 또는 치료제 |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
AU2013221585B2 (en) * | 2012-02-17 | 2017-03-30 | Seagen Inc. | Antibodies to integrin alphavbeta6 and use of same to treat cancer |
TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對il-31拮抗劑之治療的反應之方法 |
JP5954916B1 (ja) * | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物 |
US10544227B2 (en) * | 2015-04-14 | 2020-01-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient |
WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
PL234632B1 (pl) * | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
RU2758378C1 (ru) | 2018-02-09 | 2021-10-28 | Галдерма Холдинг СА | Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой |
JPWO2019225568A1 (ja) | 2018-05-21 | 2021-07-01 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
US11236157B2 (en) | 2019-01-28 | 2022-02-01 | Galderma Holding SA | Treatment of skin lesions and pruritus in prurigo nodularis patients |
JPWO2020204055A1 (pl) | 2019-04-02 | 2020-10-08 | ||
TW202128222A (zh) | 2019-11-20 | 2021-08-01 | 日商中外製藥股份有限公司 | 含有抗體之製劑 |
IL300694A (en) | 2020-09-01 | 2023-04-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient |
TW202304510A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商葛德瑪控股公司 | 結節性癢疹之治療 |
CA3229982A1 (en) | 2021-08-30 | 2023-03-09 | Galderma Holding SA | Treatments for atopic dermatitis |
WO2024047497A1 (en) | 2022-09-02 | 2024-03-07 | Galderma Holding SA | Treatments for prurigo nodularis |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
KR100371784B1 (ko) * | 1992-12-01 | 2003-07-22 | 프로테인 디자인랩스, 인코포레이티드 | L-셀렉틴과반응성인인체화된항체 |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE283926T1 (de) * | 1995-09-11 | 2004-12-15 | Kyowa Hakko Kogyo Kk | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
ES2339843T3 (es) | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | Proteina receptora de hematopoyetina novedosa, nr10. |
ES2310660T3 (es) | 2002-01-18 | 2009-01-16 | Zymogenetics, Inc. | Citoquina (ligando zcytor17). |
US7750204B2 (en) | 2002-06-05 | 2010-07-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibody |
CA2519057A1 (en) * | 2003-03-24 | 2004-10-07 | Zymogenetics, Inc. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
CA2548185A1 (en) | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | Expression systems using mammalian .beta.-actin promoter |
AU2005321017B2 (en) * | 2004-12-28 | 2011-02-24 | Innate Pharma S.A. | Monoclonal antibodies against NKG2A |
AU2006214404B2 (en) * | 2005-02-14 | 2012-03-08 | Bristol-Myers Squibb Company | Methods of treating skin disorders using an IL-31RA antagonist |
UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
KR20150091545A (ko) * | 2006-06-08 | 2015-08-11 | 추가이 세이야쿠 가부시키가이샤 | 염증성 질환의 예방 또는 치료제 |
EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
EP2426144B1 (en) * | 2007-02-23 | 2018-10-31 | Merck Sharp & Dohme Corp. | Engineered anti-il-23p19 antibodies |
EP3415529B1 (en) * | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
CN106519025B (zh) * | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
TWI578998B (zh) * | 2007-09-26 | 2017-04-21 | 中外製藥股份有限公司 | 抗il-6受體的抗體 |
MY185647A (en) * | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
TW201634479A (zh) * | 2007-12-05 | 2016-10-01 | Chugai Pharmaceutical Co Ltd | 抗nr10抗體及其應用 |
-
2009
- 2009-03-09 JP JP2009054941A patent/JP2010210772A/ja active Pending
- 2009-12-04 ES ES09830463.7T patent/ES2552690T3/es active Active
- 2009-12-04 BR BRPI0906478A patent/BRPI0906478B8/pt active IP Right Grant
- 2009-12-04 WO PCT/JP2009/070376 patent/WO2010064697A1/ja active Application Filing
- 2009-12-04 RU RU2010126078/10A patent/RU2487136C2/ru active
- 2009-12-04 PT PT98304637T patent/PT2354161E/pt unknown
- 2009-12-04 EP EP15172595.9A patent/EP2949672A1/en not_active Withdrawn
- 2009-12-04 EP EP09830463.7A patent/EP2354161B1/en active Active
- 2009-12-04 PL PL09830463T patent/PL2354161T3/pl unknown
- 2009-12-04 DK DK09830463.7T patent/DK2354161T3/en active
- 2009-12-04 KR KR1020107014700A patent/KR101271323B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BRPI0906478B1 (pt) | 2020-02-11 |
RU2010126078A (ru) | 2013-01-10 |
RU2487136C2 (ru) | 2013-07-10 |
KR101271323B1 (ko) | 2013-06-04 |
KR20100091245A (ko) | 2010-08-18 |
BRPI0906478B8 (pt) | 2021-05-25 |
EP2354161B1 (en) | 2015-08-12 |
EP2354161A4 (en) | 2013-01-02 |
PT2354161E (pt) | 2015-10-22 |
JP2010210772A (ja) | 2010-09-24 |
ES2552690T3 (es) | 2015-12-01 |
DK2354161T3 (en) | 2015-09-14 |
BRPI0906478A2 (pt) | 2015-11-24 |
EP2354161A1 (en) | 2011-08-10 |
WO2010064697A1 (ja) | 2010-06-10 |
EP2949672A1 (en) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2354161T3 (pl) | Przeciwciało anty -NR10 i jego zastosowanie | |
IL241091B (en) | Antibodies to fcrn and their use | |
IL209309A0 (en) | Anti-fn14 antibodies and uses thereof | |
IL216731A (en) | And antibodies against p95 – her2 and their uses | |
EP2236604A4 (en) | ANTI-NR10 ANTIBODIES AND USE THEREOF | |
PT2099826E (pt) | Anticorpo anti-beta-amilóide e suas utilizações | |
IL200012A0 (en) | Anti-robo4 antibodies and uses therefor | |
HK1142341A1 (en) | Anti-hepcidin antibodies and uses thereof | |
EP2334330A4 (en) | ANTI-CD147 ANTIBODIES, METHODS, AND USES | |
HK1151791A1 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
HK1156326A1 (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
HK1203206A1 (en) | Antibody and use thereof | |
EP2351732A4 (en) | NEW RAMALINE CONNECTION AND ITS USE | |
EP2399934A4 (en) | NEW MONOCLONAL ANTIBODY AND USE THEREOF | |
SI2354161T1 (sl) | Anti-NR10 protitelo in njegova uporaba | |
EP2388320A4 (en) | ANTI-HS6ST2 ANTIBODIES AND USE THEREOF | |
HRP20160578T1 (hr) | Supstituirani furankarboksamidi i njihova upotreba | |
HK1157363A1 (zh) | 抗伸展的型鞘糖脂抗體、其衍生物及用途 | |
GB0812277D0 (en) | Antibody and uses thereof | |
HK1151048A1 (en) | Anti-nr 10 antibody, and use thereof nr10 | |
ZA200905136B (en) | Anti-robo4 antibodies and uses therefor | |
PL383212A1 (pl) | Nowa DD-karboksypeptydaza, jej otrzymywanie i zastosowania | |
HU0800405D0 (en) | Ewnvironment-friendly biocidis and use thereof |